According to Wawu Biotech's announcement, the controlling shareholder of the company plans to reduce its holdings of the company's shares by no more than 4.5 million shares through bulk transactions within 3 months after 15 trading days from the date of disclosure of the announcement, accounting for 0.86% of the company's total share capital. In addition, Zhang Lu, the director and deputy general manager of the company, plans to reduce his holdings of the company's shares by no more than 300,000 shares through centralized bidding transactions within 3 months after 15 trading days from the date of disclosure of the announcement, accounting for 0.06% of the company's total share capital. The current holdings reduction plan will not cause changes in the company's control and will not affect the company's governance structure and continuous operation.

According to Wawu Biotech's announcement, the controlling shareholder of the company plans to reduce its holdings of the company's shares by no more than 4.5 million shares through bulk transactions within 3 months after 15 trading days from the date of disclosure of the announcement, accounting for 0.86% of the company's total share capital. In addition, Zhang Lu, the director and deputy general manager of the company, plans to reduce his holdings of the company's shares by no more than 300,000 shares through centralized bidding transactions within 3 months after 15 trading days from the date of disclosure of the announcement, accounting for 0.06% of the company's total share capital. The current holdings reduction plan will not cause changes in the company's control and will not affect the company's governance structure and continuous operation.